TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05844540

Intervention type: PROCEDURE
Group type: OTHER
Intervention: harvesting bone block
Description: Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Recipient site preparation
Description: At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant insertion
Description: Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion.
Study: NCT05302492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box
Description: Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
Study: NCT05529680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular mobilization and Scapular strengthening exercises
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
Study: NCT05331313

Intervention type: GENETIC
Intervention: DNA sequencing
Description: The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
Study: NCT04595851

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Reported Outcome Measure (PROM)
Description: Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Medication Review (CMR)
Description: Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.

Intervention type: OTHER
Group type: OTHER
Intervention: Communications between oncology and primary care pharmacists
Description: Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
Study: NCT05775081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedues
Description: Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedues
Description: Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
Study: NCT06229652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RASMUS Resilience Training
Description: RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-oriented Yoga
Description: Body-oriented Yoga following the Ashtanga style will be held by certified yoga teacher parallel to the experimental one hour per week 10 times.~Each yoga session will start with the proper warming up of the whole body with some stretching exercises (20 min). The main part will last about 30 minutes and consist of dynamic and active yoga sequencing containing sun salutation with a mix of exercises. A relaxation phase with controlled breathing and meditation-elements will finish the class (10 min). Each exercise has different complexity levels of implementation and will be adapted to the performance abilities of each participant.
Study: NCT06335485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will attend 4 CBT sessions prior to surgery and 2 optional sessions after surgery.
Study: NCT04898959

Intervention type: OTHER
Intervention: Filling out Questionaire
Description: Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
Study: NCT02652325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Study: NCT04705090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394 treatment
Description: Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
Study: NCT04901624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Risk Messaging
Description: Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Risk Messaging
Description: Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Risk Messaging
Description: Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Risk Messaging
Description: Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Protection
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Protection
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Incentive
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Incentive
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
Study: NCT00012909

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hormone Replacement Therapy Decision-Aid
Study: NCT06124508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Education
Description: Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-Structured Interview
Description: Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Lung Cancer Screening Program
Description: Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care Lung Cancer Screening Program
Description: Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
Study: NCT06039202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA102N
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
Study: NCT06068959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using LED
Description: Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Photobiomodulation Placebo
Study: NCT05159934

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine
Description: Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
Study: NCT04801095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WM-S1-030
Description: WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
Study: NCT04913831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline 100ml, 8-35 days, once/day, intravenous administration
Study: NCT05739916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (Before)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (After)
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (After)
Description: single dose administration (one tablet once a day)
Study: NCT06551402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate 150mg
Description: 100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: 100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
Study: NCT05668273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education with simulated patient
Description: Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education with simulator
Description: Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
Study: NCT05258552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema
Description: preoperative enema
Study: NCT05259631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
Study: NCT02652325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Povidone-Iodine USP swabs
Study: NCT06213259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6005
Description: Biological: KD6005, SQ
Study: NCT05259631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
Study: NCT04232631

Intervention type: DEVICE
Intervention: SnapshotNIR, Kent Imaging
Description: Vascular imaging device

Intervention type: DEVICE
Intervention: SnapshotNIR, Kent Imaging
Description: Vascular imaging device
Study: NCT04699539

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: in 5-6fractions with Cyberknife.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: in 5-6fractions with Cyberknife.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
Study: NCT04907123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive sodiuria-guided diuretic treatment
Description: Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard diuretic treatment
Description: Stepwise diuretic therapy based on diuresis assessment
Study: NCT05412277

Intervention type: OTHER
Group type: OTHER
Intervention: VIA Disc Nucleus Pulposus Allograft
Description: A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
Study: NCT06140290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Immediate Release (IR)
Description: An immediate release tablet
Study: NCT04968704

Intervention type: OTHER
Intervention: 3D photography and computer modelling
Description: 3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
Study: NCT06213259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6005
Description: Biological: KD6005, SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, SQ